Efficacy of Mosapride on Recovery of Intestinal Motility After Elective Colorectal Cancer Surgery
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04905147 |
Recruitment Status : Unknown
Verified September 2021 by Mahidol University.
Recruitment status was: Enrolling by invitation
First Posted : May 27, 2021
Last Update Posted : September 2, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Colorectal Cancer Bowel Ileus | Drug: Mosapride Drug: Placebo | Not Applicable |
This prospective blinded (participants,researchers,investigators) randomizedcontrolledtrial (RCT) is aimed to study the efficacy of the prokinetic agents, specifically, Mosapride on gastrointestinal recovery in patients under going colorectal cancer surgery. The patients are divided into two groups and each group will receive oral Mosapride and placebo,respectively. The primary outcome is to study the efficacy of Mosapride compared with placebo on gastrointestinal recovery in patients undergoing elective colorectal cancer surgery.
The participants were randomly assigned to receive mosapride (22patients) or to serve as placebo (22patients). Patients first were randomly assigned to one of the two groups. The mosapride group received 15 mg of mosapride by mouth or feeding via NG with 50 ml of water three times a day, starting on the morning of postoperative day 1, until hospital discharge or for a maximum of 10 postoperative days if the patient remained hospitalized. The control group received15 mg of placebo drug with 50ml of water on the same schedule.
Oral feeding was allowed when the first bowel sound and the first passage of flatus was came. A clear liquid diet is the first postoperative meal. If patient well tolerated, next step diet was applied (full liquid diet, soft diet, regular diet). Patients were discharged when the following criteria were fulfilled: 1) regular diet was tolerated without discomfort; 2) bowel movements had returned; and 3) body temperature was normal, with no major complications present.
The duration on first time bowel movement or first passage of flatus, postoperative hospital stay and adverse effects will be evaluated. The This trial was designed to have 90 percent power to detect a 20 percent decrease in median postoperative time to the first of bowel movement at a significance level of 5 percent. The necessary patient accrual to detect this difference was determined to be 20 patients per group and 10 % drop off was calculated so the totally patient was 22 patients per groups.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 44 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | The mosapride group received 15 mg of mosapride by mouth or feeding via NG with 50 ml of water three times a day, starting on the morning of postoperative day 1, until hospital discharge or for a maximum of 10 postoperative days if the patient remained hospitalized. |
Masking: | Single (Investigator) |
Primary Purpose: | Other |
Official Title: | Randomized Controlled Trials of Efficacy of Mosapride on Recovery of Intestinal Motility After Elective Colorectal Cancer Surgery |
Actual Study Start Date : | July 1, 2021 |
Estimated Primary Completion Date : | July 31, 2023 |
Estimated Study Completion Date : | November 30, 2023 |
Arm | Intervention/treatment |
---|---|
Active Comparator: The mosapride group
The mosapride group received 15 mg of mosapride by mouth or feeding via NG with 50 ml of water three times a day, starting on the morning of postoperative day 1, until hospital discharge or for a maximum of 10 postoperative days if the patient remained hospitalized.
|
Drug: Mosapride
Mosapride citrate is prokinetic drug that selectively activates 5-HT4receptors. Mosapride stimulates serotonin receptor in the digestive tract and increases acetylcholine release to promote upper digestive tract (stomach and duodenum) and lower digestive tract (colon) motility and gastric emptying without cardiac side effects
Other Name: The mosapride group |
Placebo Comparator: The control group
The control group received 15 mg of placebo drug with 50 ml of water three times a day, starting on the morning of postoperative day 1, until hospital discharge or for a maximum of 10 postoperative days if the patient remained hospitalized.
|
Drug: Placebo
Placebo drug 15 mg
Other Name: The placebo group |
- Postoperative time to the first passage of flatus. [ Time Frame: 24 hours ]Postoperative time to the first passage of flatus or the first bowel movement, as evaluated by one of the investigators (surgical resident) who was blinded as to whether the patient had received mosapride.
- Postoperative time to the first passage of flatus. [ Time Frame: 48 hours ]Postoperative time to the first passage of flatus or the first bowel movement, as evaluated by one of the investigators (surgical resident) who was blinded as to whether the patient had received mosapride.
- Postoperative time to the first passage of flatus. [ Time Frame: 72 hours ]Postoperative time to the first passage of flatus or the first bowel movement, as evaluated by one of the investigators (surgical resident) who was blinded as to whether the patient had received mosapride.
- Length of postoperative hospital stay [ Time Frame: 30 day ]Length of postoperative hospital stay, and occurrence of adverse effects
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 15 Years to 70 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients who are undergoing elective colorectal cancer surgery at Ramathibodi hospital both open and laparoscopic surgery.
- Both male and female who age between 15 to 70 years old.
- Physical status American Society of Anesthesiologists (ASA) classification1-2-3.
Exclusion Criteria:
- Metastatic disease.
- Patients who reject to participate or withdrawal from the research.
- History of Mosapride allergy.
- Pregnancy.
- Emergency colorectal cancer surgery.
- Intestinal perforation or obstruction.
- Patients who have cardiac problem (Side effects of Mosapride may include arrhythmia or QTprolong).
- Physical status American Society of Anesthesiologists (ASA) classification 4-5.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04905147
Thailand | |
Chairat Supsamutchai | |
Bangkok, Bankok, Thailand, 10400 |
Study Chair: | Chairat Supsamutchai, MD | Ramathibodi hospital, Mahidol University. | |
Study Chair: | Tharin Thampongsa, MD | Ramathibodi hospital, Mahidol University. | |
Principal Investigator: | Bensita Saengsawang, MD | Ramathibodi hospital, Mahidol University. | |
Study Director: | Jakrapan Jirasiritham, MD | Ramathibodi hospital, Mahidol University. |
Responsible Party: | Mahidol University |
ClinicalTrials.gov Identifier: | NCT04905147 |
Other Study ID Numbers: |
COA.MURA2021/328 |
First Posted: | May 27, 2021 Key Record Dates |
Last Update Posted: | September 2, 2021 |
Last Verified: | September 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Postoperative ileus Colorectal Cancer Surgery |
Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases |
Intestinal Diseases Rectal Diseases Mosapride Gastrointestinal Agents Serotonin Receptor Agonists Serotonin Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |